Overview

Gender

male

Investor Type

Angel

William Rieflin became Executive Chairman of NGM’s Board of Directors in September 2018, after having served as Chief Executive Officer of NGM and a member of the Board over the prior eight years. Prior to joining NGM, he was President of XenoPort, Inc. (NASDAQ: XNPT), which was acquired by Arbor Pharmaceuticals in 2016, and Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves on the Board of Directors of FLX Bio, Inc. and Kallyope, Inc. William Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.